ReviewCureus2025
The Role of PET Detection of Biomarkers in Early Diagnosis, Progression, and Prognosis of Alzheimer's Disease: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Astrocytic GPR55 receptors promote glycolysis.Journal of cannabis research · 2026Article
- The Prevalence of Sleep Disorders in Populations with Glymphatic Dysfunction: A Systematic Review and Meta-Analysis.Biology · 2026Review
- Effect of Structured Exercise on Blood Pressure in Patients With Rheumatoid Arthritis: A Systematic Review.Cureus · 2025Review
- Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Radiological Differentiation of Pituitary Adenomas From Other Sellar Masses: A Systematic Review.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a chronic neurologic disease characterized by the deposition of Aβ amyloid and tau protein in the neural tissue, which leads to gradual and irreversible deterioration of memory. Positron emission tomography (PET) showed high potential in diagnosing AD. It provided a unique opportunity to assess cerebral amyloid plaques and tau neurofibrillary tangle deposits in the brain tissue without invasive procedures in vivo. Many studies have been focused on PET diagnosis of AD in recent years, which has significantly improved diagnosis and treatment strategies. This review study aims to summarize the role and emphasize the benefits of PET detection of AD biomarkers in early stages, clinical and histological progression assessment, and predicting AD outcomes. Relevant articles published in the last five years, from September 1, 2019, to October 30, 2024, were searched through authentic databases such as PubMed, PubMed Central, Europe PubMed Central, Science Direct, Cochrane Library, and Google Scholar. In this systematic review, we included articles published in English, with available full text, based on human trials, with relevant information regarding participants who underwent PET of the brain to diagnose AD biomarkers. The study strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and recommendations. The Joanna Briggs Institute (JBI) critical appraisal methods were used to evaluate all selected cross-sectional research, and the Newcastle-Ottawa Scale (NOS) was used to assess the cohort and longitudinal studies. Eleven relevant articles were included in this systematic review, and 2,203 males and females participated. The study revealed that the detection of beta-amyloid PET showed high-precious results in early diagnosis of AD. The detection of tau protein showed a high potential for estimation of the clinical and histological progression and prognosis of AD in longitudinal studies. Identifying amyloid and tau protein accumulation and glucose metabolism alterations is highly predictive of neurodegeneration in preclinical and mild cognitive impairment stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.